百利天恒:双抗ADC药物非小细胞肺癌III期临床达主要终点

智通财经
Aug 17
【百利天恒:双抗ADC药物非小细胞肺癌III期临床达主要终点】百利天恒公告称,公司自主研发的全球首个且唯一获批上市的EGFR×HER3双抗ADC伦康依隆妥单抗/宜泽康,针对既往经EGFR-TKI治疗失败的EGFR敏感突变的局部晚期或转移性非小细胞肺癌的III期临床试验,经独立数据监查委员会判断,在预设的期中分析中达到无进展生存期主要终点,总生存期方面亦观察到获益趋势。这是该双抗ADC达成主要终点的第四个III期临床研究,也是全球首个双抗ADC药物在非小细胞肺癌治疗中达成主要终点的III期临床研究。目前该药物已有2项适应症获国家药监局上市批准,1项适应症的上市申请获CDE受理。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10